This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisCompetitorsDividendInsider TradesTrendsBuy This Stock Talaris Therapeutics (NASDAQ:TALS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.50%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$2.18M Get TALS Insider Trade Alerts Want to know when executives and insiders are buying or selling Talaris Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TALS Insider Buying and Selling by Quarter Talaris Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/14/2023Suzanne IldstadDirectorSell12,942$2.49$32,225.58 6/12/2023Suzanne IldstadDirectorSell16,870$2.59$43,693.30 6/9/2023Suzanne IldstadDirectorSell25,419$2.46$62,530.74 6/7/2023Suzanne IldstadDirectorSell75,001$2.39$179,252.39 6/5/2023Suzanne IldstadDirectorSell7,841$2.52$19,759.32 6/1/2023Suzanne IldstadDirectorSell15,713$2.56$40,225.28 4/21/2023Suzanne IldstadDirectorSell15,004$2.35$35,259.40 4/19/2023Suzanne IldstadDirectorSell21,753$2.16$46,986.48 4/17/2023Suzanne IldstadDirectorSell99,771$2.14$213,509.94 3/17/2023Suzanne IldstadDirectorSell10,436$2.06$21,498.16 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 3/1/2023Suzanne IldstadDirectorSell29$2.05$59.45 2/21/2023Suzanne IldstadDirectorSell3,500$2.05$7,175.00 2/16/2023Suzanne IldstadDirectorSell2,939$2.06$6,054.34 8/22/2022Suzanne IldstadInsiderSell525,000$2.80$1,470,000.00 (Data available from 1/1/2013 forward) TALS Insider Trading Activity - Frequently Asked Questions Who is on Talaris Therapeutics' Insider Roster? The list of insiders at Talaris Therapeutics includes Suzanne Ildstad. Learn more on insiders at TALS. What percentage of Talaris Therapeutics stock is owned by insiders? 16.50% of Talaris Therapeutics stock is owned by insiders. Learn more on TALS's insider holdings. More Insider Trading Tools from MarketBeat Related Companies Prime Medicine Insider Trades Inhibikase Therapeutics Insider Trades Protalix BioTherapeutics Insider Trades Invizyne Technologies Insider Trades ZIVO Bioscience Insider Trades Calidi Biotherapeutics Insider Trades Finch Therapeutics Group Insider Trades AlloVir Insider Trades NKGen Biotech Insider Trades CEL-SCI Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:TALS) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.